259 related articles for article (PubMed ID: 23093903)
1. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Nanomedicine; 2012; 7():5475-89. PubMed ID: 23093903
[TBL] [Abstract][Full Text] [Related]
2. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
3. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Pharm Res; 2012 Oct; 29(10):2845-59. PubMed ID: 22644590
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
5. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
[TBL] [Abstract][Full Text] [Related]
6. Dry powder inhaler formulations of poorly water-soluble itraconazole: A balance between in-vitro dissolution and in-vivo distribution is necessary.
Huang Z; Lin L; McGoverin C; Liu H; Wang L; Zhou QT; Lu M; Wu C
Int J Pharm; 2018 Nov; 551(1-2):103-110. PubMed ID: 30217767
[TBL] [Abstract][Full Text] [Related]
7. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
8. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
Pornputtapitak W; El-Gendy N; Berkland C
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
[TBL] [Abstract][Full Text] [Related]
9. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation.
Sun W; Ni R; Zhang X; Li LC; Mao S
Drug Dev Ind Pharm; 2015 Jun; 41(6):927-33. PubMed ID: 24785575
[TBL] [Abstract][Full Text] [Related]
10. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption.
Sun W; Mao S; Shi Y; Li LC; Fang L
J Pharm Sci; 2011 Aug; 100(8):3365-3373. PubMed ID: 21520089
[TBL] [Abstract][Full Text] [Related]
11. Antifungal efficacy of Itraconazole loaded PLGA-nanoparticles stabilized by vitamin-E TPGS: In vitro and ex vivo studies.
Alhowyan AA; Altamimi MA; Kalam MA; Khan AA; Badran M; Binkhathlan Z; Alkholief M; Alshamsan A
J Microbiol Methods; 2019 Jun; 161():87-95. PubMed ID: 30738109
[TBL] [Abstract][Full Text] [Related]
12. Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.
Keil TWM; Feldmann DP; Costabile G; Zhong Q; da Rocha S; Merkel OM
Eur J Pharm Biopharm; 2019 Oct; 143():61-69. PubMed ID: 31445157
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.
Parikh T; Sandhu HK; Talele TT; Serajuddin AT
Pharm Res; 2016 Jun; 33(6):1456-71. PubMed ID: 26951566
[TBL] [Abstract][Full Text] [Related]
14. Converting nanosuspension into inhalable and redispersible nanoparticles by combined in-situ thermal gelation and spray drying.
Wan KY; Weng J; Wong SN; Kwok PCL; Chow SF; Chow AHL
Eur J Pharm Biopharm; 2020 Apr; 149():238-247. PubMed ID: 32112895
[TBL] [Abstract][Full Text] [Related]
15. Conversion of nanosuspensions into dry powders by spray drying: a case study.
Chaubal MV; Popescu C
Pharm Res; 2008 Oct; 25(10):2302-8. PubMed ID: 18509597
[TBL] [Abstract][Full Text] [Related]
16. Development of stabilized itraconazole nanodispersions by using high-gravity technique.
Zhang ZL; Le Y; Wang JX; Zhao H; Chen JF
Drug Dev Ind Pharm; 2012 Dec; 38(12):1512-20. PubMed ID: 22435399
[TBL] [Abstract][Full Text] [Related]
17. Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components studied by a mixture design.
Foglio Bonda A; Rinaldi M; Segale L; Palugan L; Cerea M; Vecchio C; Pattarino F
Eur J Pharm Sci; 2016 Feb; 83():175-83. PubMed ID: 26742430
[TBL] [Abstract][Full Text] [Related]
18. Cryogenic liquids, nanoparticles, and microencapsulation.
Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
[TBL] [Abstract][Full Text] [Related]
19. Formulation and characterization of biocompatible and stable I.V. itraconazole nanosuspensions stabilized by a new stabilizer polyethylene glycol-poly(β-Benzyl-l-aspartate) (PEG-PBLA).
Zong L; Li X; Wang H; Cao Y; Yin L; Li M; Wei Z; Chen D; Pu X; Han J
Int J Pharm; 2017 Oct; 531(1):108-117. PubMed ID: 28830781
[TBL] [Abstract][Full Text] [Related]
20. Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole.
Kumar S; Shen J; Burgess DJ
J Control Release; 2014 Oct; 192():95-102. PubMed ID: 25009979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
